Biosimilar medicines and cost-effectiveness by Steven Simoens

Connect to this object online.

Health Economics of Antibiotics by Steven Simoens

Connect to this object online.

How to assess the value of medicines? by Steven Simoens

Connect to this object online.

Emerging Insights into European Markets of Biologics, Including Biosimilars by Steven Simoens, Isabelle Huys

Connect to this object online.

Generic Medicine Pricing Policies in Europe: Current Status and Impact by Pieter Dylst, Steven Simoens

Connect to this object online.

Tendering and biosimilars: what role for value-added services? by Steven Simoens, Raymond Cheung

Connect to this object online.

Guidance for Demonstrating the Societal Value of new Antibiotics by Steven Simoens, Isabel Spriet, Isabel Spriet

Connect to this object online.

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study by Steven Simoens, Arnold G. Vulto, Pieter Dylst

Connect to this object online.

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review by Khadidja Abdallah, Isabelle Huys, Kathleen Claes, Steven Simoens

Connect to this object online.

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks by Alessandra Blonda, Yvonne Denier, Isabelle Huys, Steven Simoens

Connect to this object online.

A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe by Khadidja Abdallah, Kris De Boeck, Marc Dooms, Steven Simoens

Connect to this object online.

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries by Alessandra Blonda, Teresa Barcina Lacosta, Mondher Toumi, Steven Simoens

Connect to this object online.

Time Investment in Drug Supply Problems by Flemish Community Pharmacies by Elfi De Weerdt, Steven Simoens, Minne Casteels, Isabelle Huys

Connect to this object online.

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries by Alessandra Blonda, Yvonne Denier, Isabelle Huys, Pawel Kawalec, Steven Simoens

Connect to this object online.

Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries by Cedric Popa, Karel Holvoet, Tessa Van Montfort, Floris Groeneveld, Steven Simoens

Connect to this object online.

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer by Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes, Steven Simoens

Connect to this object online.

Critical Reflections on Reimbursement and Access of Advanced Therapies by Steven Simoens, Katrien De Groote, Cornelis Boersma, Cornelis Boersma, Cornelis Boersma

Connect to this object online.

Economic evaluation of biosimilars for reimbursement purposes - what, when, how? by Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto, Steven Simoens

Connect to this object online.

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys

Connect to this object online.

The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys

Connect to this object online.